Treatment outcome of obsessive compulsive disorder with comorbid social phobia

J. L. Carrasco, Eric Hollander, F. R. Schneier, M. R. Liebowitz

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background: Treatment of obsessive compulsive disorder (OCD) with serotonin reuptake blockers has been demonstrated effective in 50% to 60% of patients in open and placebo-controlled studies. However, some reports indicate that comorbid Axis II psychopathology, including avoidant personality disorder, and deficiency of social skills could be predictors of a poor response to treatment in OCD patients. Method: A retrospective review elicited 12 patients who met DSM-III-R diagnostic criteria for both OCD and social phobia and were treated in our clinic last year with adequate trials of serotonin reuptake blockers or MAOIs. Results: Only 3 (27%) of the 11 patients treated with serotonin reuptake blockers had a substantial improvement of OCD symptoms. Among them, only 1 (11%) of 9 patients with generalized subtype of social phobia versus 2 (100%) of 2 patients with the nongeneralized subtype responded to serotonin reuptake blockers. Four (80%) of 5 patients with comorbid generalized social phobia receiving phenelzine had marked improvement of OCD symptoms. In general, response of social phobia occurred parallel to that of OCD. Conclusion: Comorbid generalized social phobia seems to be associated with a poor response to serotonin reuptake blockers in OCD patients. Deficient social skills, as well as distinct biological mechanisms, may be involved. MAOIs might be an effective alternative medication in refractory cases. Larger and controlled studies are needed to define the implications of the association of OCD and social phobia.

Original languageEnglish (US)
Pages (from-to)387-391
Number of pages5
JournalJournal of Clinical Psychiatry
Volume53
Issue number11
StatePublished - 1992
Externally publishedYes

Fingerprint

Obsessive-Compulsive Disorder
Serotonin
Phenelzine
Social Phobia
Personality Disorders
Psychopathology
Diagnostic and Statistical Manual of Mental Disorders
Placebos
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Carrasco, J. L., Hollander, E., Schneier, F. R., & Liebowitz, M. R. (1992). Treatment outcome of obsessive compulsive disorder with comorbid social phobia. Journal of Clinical Psychiatry, 53(11), 387-391.

Treatment outcome of obsessive compulsive disorder with comorbid social phobia. / Carrasco, J. L.; Hollander, Eric; Schneier, F. R.; Liebowitz, M. R.

In: Journal of Clinical Psychiatry, Vol. 53, No. 11, 1992, p. 387-391.

Research output: Contribution to journalArticle

Carrasco, JL, Hollander, E, Schneier, FR & Liebowitz, MR 1992, 'Treatment outcome of obsessive compulsive disorder with comorbid social phobia', Journal of Clinical Psychiatry, vol. 53, no. 11, pp. 387-391.
Carrasco, J. L. ; Hollander, Eric ; Schneier, F. R. ; Liebowitz, M. R. / Treatment outcome of obsessive compulsive disorder with comorbid social phobia. In: Journal of Clinical Psychiatry. 1992 ; Vol. 53, No. 11. pp. 387-391.
@article{4bd37d348b6542b19ce68757cd74fe3f,
title = "Treatment outcome of obsessive compulsive disorder with comorbid social phobia",
abstract = "Background: Treatment of obsessive compulsive disorder (OCD) with serotonin reuptake blockers has been demonstrated effective in 50{\%} to 60{\%} of patients in open and placebo-controlled studies. However, some reports indicate that comorbid Axis II psychopathology, including avoidant personality disorder, and deficiency of social skills could be predictors of a poor response to treatment in OCD patients. Method: A retrospective review elicited 12 patients who met DSM-III-R diagnostic criteria for both OCD and social phobia and were treated in our clinic last year with adequate trials of serotonin reuptake blockers or MAOIs. Results: Only 3 (27{\%}) of the 11 patients treated with serotonin reuptake blockers had a substantial improvement of OCD symptoms. Among them, only 1 (11{\%}) of 9 patients with generalized subtype of social phobia versus 2 (100{\%}) of 2 patients with the nongeneralized subtype responded to serotonin reuptake blockers. Four (80{\%}) of 5 patients with comorbid generalized social phobia receiving phenelzine had marked improvement of OCD symptoms. In general, response of social phobia occurred parallel to that of OCD. Conclusion: Comorbid generalized social phobia seems to be associated with a poor response to serotonin reuptake blockers in OCD patients. Deficient social skills, as well as distinct biological mechanisms, may be involved. MAOIs might be an effective alternative medication in refractory cases. Larger and controlled studies are needed to define the implications of the association of OCD and social phobia.",
author = "Carrasco, {J. L.} and Eric Hollander and Schneier, {F. R.} and Liebowitz, {M. R.}",
year = "1992",
language = "English (US)",
volume = "53",
pages = "387--391",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "11",

}

TY - JOUR

T1 - Treatment outcome of obsessive compulsive disorder with comorbid social phobia

AU - Carrasco, J. L.

AU - Hollander, Eric

AU - Schneier, F. R.

AU - Liebowitz, M. R.

PY - 1992

Y1 - 1992

N2 - Background: Treatment of obsessive compulsive disorder (OCD) with serotonin reuptake blockers has been demonstrated effective in 50% to 60% of patients in open and placebo-controlled studies. However, some reports indicate that comorbid Axis II psychopathology, including avoidant personality disorder, and deficiency of social skills could be predictors of a poor response to treatment in OCD patients. Method: A retrospective review elicited 12 patients who met DSM-III-R diagnostic criteria for both OCD and social phobia and were treated in our clinic last year with adequate trials of serotonin reuptake blockers or MAOIs. Results: Only 3 (27%) of the 11 patients treated with serotonin reuptake blockers had a substantial improvement of OCD symptoms. Among them, only 1 (11%) of 9 patients with generalized subtype of social phobia versus 2 (100%) of 2 patients with the nongeneralized subtype responded to serotonin reuptake blockers. Four (80%) of 5 patients with comorbid generalized social phobia receiving phenelzine had marked improvement of OCD symptoms. In general, response of social phobia occurred parallel to that of OCD. Conclusion: Comorbid generalized social phobia seems to be associated with a poor response to serotonin reuptake blockers in OCD patients. Deficient social skills, as well as distinct biological mechanisms, may be involved. MAOIs might be an effective alternative medication in refractory cases. Larger and controlled studies are needed to define the implications of the association of OCD and social phobia.

AB - Background: Treatment of obsessive compulsive disorder (OCD) with serotonin reuptake blockers has been demonstrated effective in 50% to 60% of patients in open and placebo-controlled studies. However, some reports indicate that comorbid Axis II psychopathology, including avoidant personality disorder, and deficiency of social skills could be predictors of a poor response to treatment in OCD patients. Method: A retrospective review elicited 12 patients who met DSM-III-R diagnostic criteria for both OCD and social phobia and were treated in our clinic last year with adequate trials of serotonin reuptake blockers or MAOIs. Results: Only 3 (27%) of the 11 patients treated with serotonin reuptake blockers had a substantial improvement of OCD symptoms. Among them, only 1 (11%) of 9 patients with generalized subtype of social phobia versus 2 (100%) of 2 patients with the nongeneralized subtype responded to serotonin reuptake blockers. Four (80%) of 5 patients with comorbid generalized social phobia receiving phenelzine had marked improvement of OCD symptoms. In general, response of social phobia occurred parallel to that of OCD. Conclusion: Comorbid generalized social phobia seems to be associated with a poor response to serotonin reuptake blockers in OCD patients. Deficient social skills, as well as distinct biological mechanisms, may be involved. MAOIs might be an effective alternative medication in refractory cases. Larger and controlled studies are needed to define the implications of the association of OCD and social phobia.

UR - http://www.scopus.com/inward/record.url?scp=0026480248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026480248&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 387

EP - 391

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 11

ER -